Genetic testing in paediatric neurological disorders
Developmental Medicine & Child Neurology · 29.07.2026
DOI: 10.1111/dmcn.70430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Medicine & Child Neurology, online erschienen am 29.07.2026. Verfasst von Wafa Bani Uraba und 9 weiteren Autor:innen. Beteiligte Einrichtung: TY Nelson Department of Neurology and Neurosurgery, The Children's Hospital at Westmead, Sydney, NSW, Australia. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
To evaluate genetic testing practices (exome sequencing, commercial panel, and in‐house genetic panels) from a large tertiary hospital for determining gaps, and to identify clinical associations with pathogenic genetic variants.
Method
This retrospective cohort study included patients (age < 18 years) from a neurology department for whom genetic testing was requested for neurological disorders, epilepsy, and movement disorders (2020–2023). Logistic regression was used to identify clinical features predictive of positive results. The clinical benefits of genetic testing were studied.
Results
Three hundred and ninety patients underwent genetic testing by exome sequencing ( n = 125), commercial panel ( n = 143), in‐house epilepsy ( n = 78), and movement disorder ( n = 44) gene panels. Exome sequencing had the highest pathogenic yield ( n = 49, 39%), followed by epilepsy ( n = 22, 28%), movement disorder ( n = 11, 25%), and commercial ( n = 22, 15%) panels. Variants of uncertain significance were highest in commercial (64%) and epilepsy (34%) panels. Among the exome sequencing cohort, the predominant clinical features were developmental delay (89%), intellectual disability (51%), and epilepsy (35%). Pathogenic variants in the exome sequencing cohort were more likely in patients with severe developmental delay (33%, p = 0.03) and hypotonia (39%, p = 0.05). There was significant utility of genetic testing in informing clinical decision making (49% of pathogenic variants in exome sequencing cohort). Intepretation Exome sequencing outperforms gene panels in confirming genetic diagnoses in paediatric neurological disorders, and highlights the need for building local diagnostic genetic‐testing resources.
Autor:innen und Institutionen
- TY Nelson Department of Neurology and Neurosurgery, The Children's Hospital at Westmead, Sydney, NSW, Australia.
- The Children's Hospital at Westmead Clinical School, The University of Sydney, Sydney, NSW, Australia.
- Kids Neuroscience Centre, The Children's Hospital at Westmead, Sydney, NSW, Australia.
- Western Sydney Genetics Program, The Children's Hospital at Westmead, Sydney, NSW, Australia.
- Randwick Genomics, NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW, Australia.
ORCID-Profile: Russell C Dale, Kavitha Kothur
Zitieren
APA
Uraba, W. B., Lee, B. C., Mohammad, S. S., Fisk, K., Buckley, M., Dale, R. C., Roscioli, T., Paediatric Neurogenomic Working Group, Gill, D., & Kothur, K. (2026). Genetic testing in paediatric neurological disorders. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.70430
Vancouver
Uraba WB, Lee BC, Mohammad SS, Fisk K, Buckley M, Dale RC, et al. Genetic testing in paediatric neurological disorders. Developmental Medicine & Child Neurology. 2026. doi:10.1111/dmcn.70430
BibTeX
@article{Uraba2026,
author = {Uraba, Wafa Bani and Lee, Byoung Chan and Mohammad, Shekeeb S and Fisk, Katrina and Buckley, Michael and Dale, Russell C and Roscioli, Tony and Paediatric Neurogenomic Working Group, Paediatric Neurogenomic Working Group and Gill, Deepak and Kothur, Kavitha},
title = {Genetic testing in paediatric neurological disorders},
journal = {Developmental Medicine & Child Neurology},
year = {2026},
doi = {10.1111/dmcn.70430}
}
EUVIMED